Skip to main
DCTH

Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems (DCTH) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Delcath Systems Inc. is actively expanding its treatment centers and anticipates positive data from clinical trials, which could enhance the adoption of its Melphalan Hydrochloride for Injection product and related delivery system. The company is projecting growth in its total revenues to $343 million by 2032 and expects improvements in margins to offset a slight reduction in revenue projections, indicating strong operational management and strategic foresight. Additionally, with the anticipated publication of the CHOPIN trial data and ongoing site activations, there is a positive trajectory for the establishment of Hepzato in the U.S. market, suggesting solid growth potential despite pricing adjustments.

Bears say

Delcath Systems Inc. faces significant headwinds, with preliminary third-quarter 2025 revenues reported at $20.5 million, marking a 15% decline from the previous quarter and falling short of consensus estimates. The company has revised its full-year revenue guidance down to $83 million to $85 million from an earlier projection of $93 million to $96 million, reflecting challenges such as slowed site activations and seasonal impacts on patient starts. Furthermore, the anticipated decrease in average revenue per kit due to the Medicaid National Drug Rebate Agreement Program adds to the financial pressures, warranting a cautious outlook on the company's future revenue performance.

Delcath Systems (DCTH) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Delcath Systems (DCTH) Forecast

Analysts have given Delcath Systems (DCTH) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Delcath Systems (DCTH) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Delcath Systems (DCTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.